TargetMol
YOUR TARGET MOLECULES

INHIBITORS & AGONISTS OF SIGNALING PATHWAYS

activate your research with inhibitors & agonists



Facebook

LinkedIn

Instagram

inquiry@targetmol.com

(781) 999-4286

Official Website
https://www.targetmol.com/

36 Washington Street, Wellesley Hills, MA 02481 USA

Targetmol Chemicals Inc.

— Your Target Molecules (Compound Libraries, Inhibitors & Agonists, Natural Products, Recombinant Proteins, Technical Services)

About Us

TargetMol Chemicals Inc. is headquartered in the Greater Boston area, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 50+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and inhibitors & agonists.

TargetMol diligently updates and offers over 800 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, agonists, natural products, peptides, antibodies, and biologics including recombinant proteins and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.

With our high-quality products & services, fast & efficient global supply chain, and professional technical support, we believe we will help you shorten your research process and yield a more successful result.

20,000+
Tool Compounds

800+
Compound Libraries

16,000+
Natural Products

Small Molecule Inhibitors & Agonists

Small molecule inhibitors & agonists can bind to targets (proteins/genes/RNA) and reduce their biological activity. They are used as tool compounds in biological and pharmacological research.

Small molecule inhibitors & agonists have many advantages:

- High purity with clear chemical composition
- More stable and low variation between batches
- Dose response is informative
- Dose can be easily manipulated
- Cell-permeable, no transfection agents required
- Act by inhibiting or inactivating specific targets

TargetMol can provide a variety of small molecule inhibitors & agonists of hot signaling pathways for research and development.

Our Advantages

High Quality

We ensure the highest quality standards for all our products using HPLC, NMR and LC/MS tests.

Competitive Price

Along with guaranteed quality standards, we also ensure the most competitive prices.

Citations

TargetMol® has earned an award for a fast increase in the number of citations in 2023.

WINNER

TARGETMOL

BIOCHEMICAL SUPPLIER TO WATCH IN 2023

2023 AWARDS

CiteAb

Science
VOLUME 368ISSUE 6497I19 JUN 2020

Nature
Volume 582 Issue 7811, 11 June 2020

Nature
2021 592(7854) 469-473

Nature
2020 588(7838) 479-484

Nature
2022, 609(7928) 854-859



Cell
VOLUME 182, ISSUE 2, P417-428.E13, JULY 23, 2020

Cancer Cell
2020, 38(5) 734-747. e9

Cell
2022, 185(23): 4361-4375. e19

Immunity
2021 54(6) 1123-1136. e8.-22.553



Immunity
2020 52(4) 620-634. e6

Immunity
55(9), 1594-1608.e6.

Cell Research
33(1), 46-54



Cancer Discovery
12(2), 356-371

Cancer Cell
Volume 41 Issue 1 p181-195

Gastroenterology
Volume 164 Issue 7 p1232-1247



Journal of Medical Virology
Volume 94 Number12 Dec 2022

TargetMol
YOUR TARGET MOLECULES

Publications Citing TargetMol Products


Article

Feeding induces cholesterol biosynthesis via the mTORC1–USP20–HMGCR axis

https://doi.org/10.1038/s41586-020-2928-y
Received: 13 November 2019
Accepted: 19 August 2020
Check for updates

Xiao-Yi Lu[1,2], Xiong-Jie Shi[1,3], Ao Hu[1,2], Ju-Qiong Wang[1,2], Yi Ding[1], Wei Jiang[1], Ming Sun[1], Xiaolu Zhao[1], Jie Luo[1], Wei-Qi[4] & Bao-Liang Song[1,2]

Cholesterol is an essential lipid and its synthesis is nutritionally and energetically costly[1,2]. In mammals, cholesterol biosynthesis increases after feeding and is inhibited under fasting conditions[3]. However, the regulatory mechanisms of cholesterol biosynthesis at the fasting–feeding transition remain poorly understood. Here we show that the deubiquitylase ubiquitin-specific peptidase 20 (USP20) stabilizes HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the cholesterol biosynthetic pathway, in the feeding state. The post-prandial increase in insulin and glucose concentration stimulates mTORC1 to phosphorylate USP20 at S132 and S134; USP20 is recruited to the HMGCR complex and antagonizes its degradation. The feeding-induced stabilization of HMGCR is abolished in mice with liver-specific *Usp20* deletion and in USP20(S132A/S134A)-knock-in mice. Genetic deletion or

(Ub–AFC) and Flag–ubiquitin from Boston Biochem; dorsomorphin 2HCl (AMPK inhibitor), A-769662 (AMPK activator) and torin1 (mTOR inhibitor) from Target Molecule; wortmannin, AKT1/2 kinase inhibi-

that inhibitors of USP20 could be used to lower cholesterol levels to treat metabolic diseases including hyperlipidaemia, liver steatosis, obesity and diabetes.


Cancer Cell

Article

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism

Graphical abstract

Authors

Koki Ueda, Rajni Kumari, Emily Schwenger, ..., Jacqueline Boultwood, Amit Verma, Ulrich Steidl

Correspondence

ulrich.steidl@einsteinmed.org

In brief

Using mouse models and data from MDS patients, Ueda et al. identify MDMX as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism across multiple different genetic disease subtypes. MDMX physically interacts with CK1α, inducing accumulation of β-Catenin. Blocking both canonical and

preleukemia/leukemia.


Letter

https://doi.org/10.1038/s41586-019-1469-8

Molecular architecture of lineage allocation and tissue organization in early mouse embryo

Guangdun Peng[1,2,3,4,11,12✉], Shengbao Suo[5,10,11], Guizhong Cui[1,11], Fang Yu[1,11], r an Wang[1], Jun Chen[1], Shirui Chen[1], Zhiwen Liu[1], Guoyu Chen[5], Yun Qian[1], Patrick P. L. tam[6,7], Jing–Dong J. Han[2,8,12✉] & Naihe Jing[1,4,9,12✉]

During post-implantation development of the mouse embryo, descendants of the inner cell mass in the early epiblast transit from the naive to primed pluripotent state[1]. Concurrently, germ layers are formed and cell lineages are specified, leading to the establishment of the blueprint for embryogenesis. Fate-mapping and lineage-analysis studies have revealed that cells in different regions of the germ layers acquire location-specific cell fates during gastrulation[2–7]. The regionalization of cell fates preceding the formation of the basic body plan—the mechanisms of which are instrumental for understanding embryonic programming and stem-cell-based translational study[8]—is conserved in vertebrate

profile of coding and noncoding transcripts in defined locations in the germ layers of E5.5 to E7.5 mouse embryos, which could be rendered digitally for visualizing in high-resolution 2D corn plots (Fig. 1b and Extended Data Fig. 1f–i) and a 3D anatomical template[9,10] (Methods). The identification of region-specific transcripts provides a molecular entry point for functional analysis. For example, the knockout of posterior-enriched long non-coding RNAs (lncRNAs) *3100004A29Rik* and *RP23-458G12.2*(Extended Data Fig. 2) led to the dysregulation of mesendoderm-related genes in the differentiating embryonic stem cells, which suggests that these non-coding transcripts have a role in regulating the differentiation of cell lineages derived from the posterior

Yap inhibitor verteporfin (TargetMol; T3112).

spatiotemporal transcriptome provides high-resolution digitized in situ gene-expression profiles, reveals the molecular genealogy of tissue lineages and defines the continuum of pluripotency states in time and space. The transcriptome further identifies the networks of molecular determinants that drive lineage specification and tissue patterning, supports a role of Hippo–Yap signalling in germ-layer development and reveals the contribution of visceral endoderm to

development of the mouse embryos. We used the single-cell regulatory network inference and clustering (SCENIC) pipeline[10] to measure regulon activities in the cell-population samples (Extended Data Fig. 3a and Methods). The regulon-based phylogenetic tree showed that the samples could be divided into six groups that represent the major tissue types of early embryos: pre- and peri-implantation, epiblast, primitive streak, ectoderm, mesoderm and endoderm (Fig. 1c


nature biotechnology

Articles

https://doi.org/10.1038/s41587-021-00946-z

Check for updates

Prediction of drug efficacy from transcriptional profiles with deep learning

Jie Zhu[1,2,6], Jingxiang Wang[3,6], Xin Wang[2,6], Mingjing Gao[3,6], Bingbing Guo[4,6], Miaomiao Gao[1], Jiarui Liu[4], Yanqiu Yu[1], Liang Wang[2], Weikaixin Kong[5], Yongpan An[2], Zurui Liu[2], Xinpei Sun[1], Zhuo Huang[5], Hong Zhou[2,7] ✉, Ning Zhang[1,7] ✉, Ruimao Zheng[4,7] ✉and Zhengwei Xie[1,3,7] ✉

Drug discovery focused on target proteins has been a successful strategy, but many diseases and biological processes lack obvious targets to enable such approaches. Here, to overcome this challenge, we describe a deep learning–based efficacy prediction system (DLEPS) that identifies drug candidates using a change in the gene expression profile in the diseased state as input. DLEPS was trained using chemically induced changes in transcriptional profiles from the LINCS project. We found that the changes in transcriptional profiles for previously unexamined molecules were predicted with a Pearson correlation coefficient of 0.76. We examined three disorders and experimentally tested the top drug candidates in mouse disease models. Validation showed that perillen, chikusetsusaponin IV and tramiprosate confer disease-relevant impacts against obesity, hypercalcemia and neurodegenerative phenotypes, respectively. DLEPS can generate insights into pathogenic mechanisms, and we demonstrate that

chemiluminescence assay kit was purchased from Bio-Rad. Isoginkgetin (CAS 548-19-6, catalog no. T4S21320), loureirin B (CAS 119425-90-0, catalog no. T3876) and chikusetsusaponin IV (CAS 7518-22-1, catalog no. T4S0290) were purchased from TargetMol. Mudanpioside C (CAS 172760-03-1, catalog no. DM0065), agnuside

puter vision and so on) suggest the potential of advanced algorithms for the assessment of chemicals in applications such as molecular encoding, chemical synthesis route planning and inhibitor target prediction[7–9]. Combined with resources developed in computational chemistry, these deep learning tools are changing

to develop as treatments for most diseases. First, we constructed a neural network using simplified molecular-input line-entry system (SMILES) chemical encoding as input to fit CTPs that were measured in the L1000 project[7] (Fig. 1a). Second, using gene signatures specific to pathological contexts, we employed gene set enrichment


Article

Structures of full-length glycoprotein hormone receptor signalling complexes

https://doi.org/10.1038/s41586-021-03924-2
Received: 18 November 2020
Accepted: 18 August 2021
Check for updates

Jia Duan[1,2,9], Peiyu Xu[1,2,9], Xi Cheng[3,9], Chunyou Mao[1,2,4,5,6,9,10], Tristan Croll[7], Xinheng He[1], Jingjing Shi[1], Xiaodong Luan[1,2,4,5], Wanchao Yin[1], Erli You[1], Qiufeng Liu[1], Shuyang Zhang[1,2,5], Hualiang Jiang[1,2,5], Yan Zhang[1,2,5,8] ✉, Yi Jiang[1,2,5] ✉ & H. Eric Xu[1,2,5,8] ✉

Luteinizing hormone and chorionic gonadotropin are glycoprotein hormones that are related to follicle-stimulating hormone and thyroid-stimulating hormone[1,2]. Luteinizing hormone and chorionic gonadotropin are essential to human reproduction and are important therapeutic drugs[3–6]. They activate the same G-protein-coupled receptor, luteinizing hormone–choriogonadotropin receptor (LHCGR), by binding to the large extracellular domain[7]. Here we report four cryo-electron microscopy structures of LHCGR: two structures of the wild-type receptor in the inactive and active states; and two structures of the constitutively active mutated receptor. The active structures are bound to heterotrimeric gonadotropin and the stimulatory G protein (G_s), and one of the structures also contains Org43553, an allosteric agonist[7]. The structures reveal a distinct 'push-and-pull' mechanism of receptor activation, in which the extracellular domain is pushed by the bound

CaCl2 supplemented with Protease Inhibitor Cocktail, EDTA-Free (TargetMol). The CG–LHCGR–G_s complex was formed in membranes by the

as a tethered agonist to induce conformational changes in the transmembrane domain and G-protein coupling. Org43553 binds to a pocket of the transmembrane domain and interacts directly with P10, which further stabilizes the active conformation. Together, these structures provide a common model for understanding the signalling of


Article

Time-resolved protein activation by proximal decaging in living systems

https://doi.org/10.1038/s41586-019-1188-1

Jie Wang[1,2,3], Yuan liu[1,3], Yanjun liu[1,3], Siqi Zheng[1], Xin Wang[1,2], Jingyi Zhao[1,2], Fan Yang[1], Gong Zhang[1], chu Wang[1,3,4]✉ & Peng r. chen[1,2,3,4]✉

A universal gain-of-function approach for selective and temporal control of protein activity in living systems is crucial to understanding dynamic cellular processes. Here we report development of a computationally aided and genetically encoded proximal decaging (hereafter, CAGE–prox) strategy that enables time-resolved activation of a broad range of proteins in living cells and mice. Temporal blockage of protein activity was computationally designed and realized by genetic incorporation of a photo-caged amino acid in proximity to the functional site of the protein, which can be rapidly removed upon decaging, resulting in protein re-activation. We demonstrate the wide applicability of our method on diverse protein families, which enabled orthogonal tuning of cell signalling and immune responses, temporal profiling of proteolytic substrates upon caspase activation as well as the development of protein-based pro-drug therapy. We envision that CAGE-prox will open opportunities for the gain-of-function study of proteins and dynamic biological processes with high precision and temporal resolution.

Precise perturbation of protein activity with high selectivity and temporal resolution is crucial to dissect various dynamic biological processes

of 0.5 mg kg^{-1} of pentostatin (Targetmol, T4006) and 10 mg kg^{-1} of cyclophos-

to fulfil the requirement of high selectivity or temporal resolution. An array of pharmacological and protein engineering-enabled approaches, including the Bump-and-hole[1,2], PROTAC[3], LARIAT[4], trim-away strategies[5] and engineering extrinsic disorder[6] have successfully

by a universal caged amino acid introduced in close proximity to its functional site and is then re-activated promptly upon photo-decaging that focuses on a specific catalytic residue. CAGE-prox relies on a Bump and hole approach to block the activity of a wide range of proteins regardless of the existence and/or chemical identity

For more product information, please check our website www.targetmol.com

TargetMol
YOUR TARGET MOLECULES

Citation Rewards Program

Cite TargetMol in your scientific articles! Claim your reward following our Citation Rewards Program.

Publications	Redemption Option	Impact Factor
Science, Nature, Cell	$300 Amazon Gift Card or $600 coupon	/
SCI	$150 Amazon Gift Card or $300 coupon	IF≥10
SCI	$100 Amazon Gift Card or $200 coupon	5≤IF<10
SCI	$50 Amazon Gift Card or $100 coupon	1≤IF<5

For further information, please visit www.targetmol.com or contact marketing@targetmol.com

TargetMol reserves the right to modify or cancel the program at any time.

*All products are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.

Contents

Angiogenesis 01
Apoptosis 04
Autophagy 07
Cell Cycle & Checkpoint 09
Chromatin & Epigenetic 11
Cytoskeletal Signaling 15
DNA Damage & DNA Repair 17
Endocrinology & Hormones 19
GPCR & G Protein 21
Immunology & Inflammation 24
JAK & STAT Signaling 27
MAPK 29
Membrane Transporter & Ion Channel 32
Metabolism 35
Microbiology & Virology 38
Neuroscience 40
NF-κB 43
PI3K & Akt & mTOR signaling 45
Stem Cell 48
Tyrosine Kinase & Adaptors 50
Ubiquitination 53

For more product information, please check our website www.targetmol.com

Compound Libraries, Inhibitors & Agonists, Natural Products, Recombinant Proteins, Technical Services



EGFR

ID	CAS Number	Product Name	Target	Condition	Indication
T21312	850140-72-6	Afatinib	Autophagy; EGFR	Marketed; Phase 1	Carcinoma, Non-Small-Cell Lung; locally advanced or metastatic non-small cell lung Cancer (NSCLC)
T19814	179688-29-0	CP-380736	EGFR		
T16369	847949-49-9	O-Desmethyl gefitinib	EGFR		
T11213	2071195-74-7	Epertinib hydrochloride	EGFR; HER		
T11161	2267329-76-8	EGFR-IN-7	EGFR	Preclinical	Non-small cell lung cancer
T2063	118409-57-7	Tyrphostin 23	EGFR	Preclinical no development reported	Cancer; Psoriasis

FGFR

ID	CAS Number	Product Name	Target	Condition	Indication
T22306	T22306	DGY-06-116	FGFR; Src		
T12401	1513857-77-6	Pemigatinib	FGFR	Marketed; Phase 3	Bladder cancer; Lymphoma; Myeloproliferative disorders; Solid tumours; Urogenital cancer; Cholangiocarcinoma
T4235	1708971-55-4	Roblitinib	FGFR	Phase 1/2	Liver Cancer; Solid tumours
T4075	1308672-74-3	Sulfatinib	FGFR; HER; VEGFR	Phase 2/3	Biliary cancer; Solid tumours; Thyroid cancer
T3726	1346242-81-6	Erdafitinib	Apoptosis; FGFR	Marketed; Phase 3	Cholangiocarcinoma; Gastric Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung Cancer; Oesophageal Cancer; Solid tumours; Urogenital Cancer
T3714	704869-38-5	SUN11602	ERK; FGFR		
T3492	192705-79-6	PD-166866	Autophagy; FGFR	No development reported	Atherosclerosis; Cancer; Coronary artery restenosis; Transplant rejection
T3456	1707289-21-1	Fisogatinib	FGFR	Phase 1/2	Cholangiocarcinoma; Liver Cancer

VEGFR

ID	CAS Number	Product Name	Target	Condition	Indication
T22432	62540-08-3	SU5208	VEGFR		
T22431	186611-11-0	SU5204	EGFR; HER; VEGFR		
T17219	212141-54-3	Vatalanib free base	VEGFR	Phase 3	Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms
T6199	1211441-98-3	Ribociclib	CDK; VEGFR	Marketed; Phase 3	Breast Cancer; Cancer; Ovarian Cancer; Peritoneal Cancer
T6184	252916-29-3	Orantinib	Apoptosis; FGFR; PDGFR; VEGFR	Phase 3	Unspecified Adult Solid Tumor, Protocol Specific
T6166	332012-40-5	Telatinib	c-Kit; PDGFR; VEGFR	Phase 2	Gastric Cancer
T6154	658084-23-2	SU11274	Apoptosis; Autophagy; CDK; c-Met/HGFR; FGFR; VEGFR	Preclinical no development reported	Cancer
T4554	71308-34-4	AG 1406	VEGFR		
T4425	942655-44-9	JK-P3	VEGFR		
T30855	234772-64-6	CGP77675	Bcr-Abl; EGFR; Src; VEGFR		

HER

ID	CAS Number	Product Name	Target	Condition	Indication
T22431	186611-11-0	SU5204	EGFR; HER; VEGFR		
T11213	2071195-74-7	Epertinib hydrochloride	EGFR; HER		
T7819	2088323-16-2	TAS0728	EGFR; HER	Phase 1/2	Advanced Solid Tumors; HER2 Abnormalities; HER3 Abnormalities
T6712	148741-30-4	Tyrphostin AG 879	Apoptosis; EGFR; HER; PDGFR; Trk receptor		
T6341	908115-27-5	PF04929113	HER; HSP	Phase 2	Cancer
T5398	T5398	BMS 599626 2HCl (873837-23-1(HCl))	HER	Phase 1 Discontinued	Breast Cancer; Glioma; Non-small cell lung Cancer; Solid tumours
T4342	1173111-67-5	PF-04929113 Mesylate	HER; HSP	Phase 2	Cancer
T4075	1308672-74-3	Sulfatinib	FGFR; HER; VEGFR	Phase 2/3	Biliary cancer; Solid tumours; Thyroid cancer
T3673	55481-88-4	Mollugin	HER; JAK		

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T10799	2304344-56-5	CHMFL-ABL-039	Bcr-Abl		
T10800	2270879-07-5	CHMFL-ABL-121	Bcr-Abl		
T38562	1175017-90-9	AKN-028	FLT	Phase 1/2	Acute Myeloid Leukemia
T7836	1357171-62-0	ML228	HIF		
T11710	2096999-92-5	JAK-IN-5	JAK		
T12549	916742-11-5	JAK-IN-11	JAK		
T13571	916741-98-5	JAK-IN-10	JAK		
T7836	1357171-62-0	ML228	HIF		
T24730	29574-21-8	Roslin 2 bromide	FAK; p53		
T10927	428478-94-8	Cyt-PTPε Inhibitor-1	Phosphatase; Src		
T32613	1962928-28-4	LCB 03-0110 dihydrochloride	Src		
TQ0132	1435934-25-0	A 419259 trihydrochloride	Src		



TNF-α

ID	CAS Number	Product Name	Target	Condition	Indication
T15437	1622849-43-7	GSK3145095	RIP kinase	Phase 2	Neoplasms, Pancreatic
T13951	1515888-53-5	UCB-9260	TNF		
T1265	60719-84-8	Amrinone	PDE; TNF	Marketed	Heart Failure
T0213	50-35-1	Thalidomide	Apoptosis; TNF; Autophagy; Ligand for E3 Ligase; Molecular Glues;	Marketed; Phase 4	Leprosy; Multiple myeloma; Peritoneal Dialysis; Malnutrition
T0131	481-49-2	Cepharanthine	Apoptosis; Autophagy; HIV Protease; TNF	Discontinued; Marketed; Preclinical	Cancer; HIV-1 infections; Cholangiocarcinoma; Infections; Inflammation; Neurological disorders; Oesophageal cancer; promotes leukocytosis

Caspase

ID	CAS Number	Product Name	Target	Condition	Indication
T2503	315183-21-2	PAC-1	Apoptosis; Autophagy; Caspase	Phase 1/2	Anaplastic astrocytoma; Glioblastoma
T0282	1135695-98-5	Q-VD-OPH	Caspase; HIV Protease		
T1772	79183-19-0	MDK83190	Apoptosis; Caspase		
T2122	1072833-77-2	Ixazomib	Autophagy; Caspase; Proteasome	Marketed; Phase 4	Amyloid light-chain amyloidosis; Multiple myeloma

Mdm2

ID	CAS Number	Product Name	Target	Condition	Indication
T21773	1253491-42-7	SP-141	Mdm2		
T11980	2136247-12-4	MD-224	E1/E2/E3 Enzyme; Mdm2; PROTACs	Preclinical	Leukaemia
T3517	1309684-94-3	RO8994	E1/E2/E3 Enzyme; Mdm2; p53		
T3184	66592-89-0	Kevetrin hydrochloride	Mdm2; p53	Phase 2; Preclinical	Acute myeloid leukaemia; Ovarian Cancer
T2243	881202-45-5	Serdemetan	Apoptosis; E1/E2/E3 Enzyme; Mdm2; p53	Phase 1	Non-small cell lung Cancer; Prostate Cancer; Solid tumours
T2179	38748-32-2	Triptolide	Apoptosis; HSP; Mdm2; NF-κB	Marketed; Phase 3; Preclinical no development reported	HIV-infection/AIDS; Inflammation; Psoriasis (psoriasis)

P53

ID	CAS Number	Product Name	Target	Condition	Indication
T7703	874146-69-7	PK11007	p53; Reactive Oxygen Species		
T6910	803647-40-7	NSC59984	p53		
T2707	63208-82-2	Pifithrin-α hydrobromide	Aryl Hydrocarbon Receptor; Ferroptosis; p53		
T2464	71555-25-4	ZMC1	p53		
T3637	511296-88-1	Pifithrin-β hydrobromide	Ferroptosis; p53		

Bcl-2

ID	CAS Number	Product Name	Target	Condition	Indication
T14376	1357576-48-7	AZD4320	BCL	Preclinical	Haematological malignancies; Mantle-cell lymphoma; Small cell lung cancer
T1119	136236-51-6	Rasagiline	BCL; MAO; Monoamine Oxidase	Marketed; Phase 4	Parkinsonian disorders; Parkinson's disease
T0186	148408-66-6	Docetaxel trihydrate	Apoptosis; BCL; Microtubule Associated	Marketed; Phase 3; Preclinical	Adenocarcinoma; Breast Cancer; Head and neck Cancer; Non-small cell lung Cancer; Prostate Cancer; Breast Neoplasms; Cancer
T0448	51146-56-6	(S)-(+)-Ibuprofen	BCL; COX; Cysteine Protease; PPAR; Thrombin	Marketed	Back Pain; Dysmenorrhoea; Headache; Inflammation; Musculoskeletal Pain; Osteoarthritis; Pain; Postoperative Pain; Rheumatic Disorders
T1980	65673-63-4	HA14-1	BCL	Preclinical no development reported	Cancer
T2099	852808-04-9	ABT-737	Autophagy; BCL; Mitophagy	Preclinical no development reported	Cancer

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T12730	1481641-08-0	RIPK1-IN-4	RIP kinase		
T27242	342808-40-6	EF24	Caspase; ERK; MEK		
T28509	286008-51-3	RDR03871	Mdm2		
T16771	1416663-77-8	RO-5963	Mdm2; p53		
T12997	2413286-32-3	SR-318	p38 MAPK; TNF		
T24730	29574-21-8	Roslin 2 bromide	FAK; p53		
T9651	2628506-54-5	PD-1/PD-L1-IN-9	PD-1/PD-L1		
T9305	1391980-92-9	Necroptosis-IN-1	RIP kinase		
T11501	2361146-30-5	GSK840	RIP kinase		
T12728	1398053-50-3	RIP2 Kinase Inhibitor 3	Others; RIP kinase		



Lysosomal Autophagy

ID	CAS Number	Product Name	Target	Condition	Indication
T3437	1391426-24-6	Lys05	Autophagy; lysosomal autophagy		
T1885	224177-60-0	Siramesine hydrochloride	Ferroptosis; lysosomal autophagy; Sigma receptor	Preclinical Discontinued	Anxiety disorders; Cancer; Major depressive disorder

CXCR

ID	CAS Number	Product Name	Target	Condition	Indication
T17208	1373268-67-7	USL311	CXCR	Phase 1/2	Solid Tumors (Phase 1) Relapsed/Recurrent GBM (Phase 2)
T14665L	T14665L	Motixafortide TFA(664334-36-5,Free)	CXCR	Phase 3	Stem cell mobilisation
T10297L	473719-41-4	AMG 487	CXCR		
T8497	1648843-04-2	SX-682	CXCR	Phase 1/2	Melanoma Stage IiiMelanoma Stage Iv
T7681	878385-84-3	AZD-5069	CXCR	Phase 2	Bladder Cancer; Coronary disorders; Head and neck Cancer; Non-small cell lung Cancer; Solid tumours
T10905	1873376-49-8	CXCR2-IN-1	CXCR		
T12269	1060524-97-1	NUCC-390	CXCR		
T11179	688763-64-6	Elubrixin	CXCR; IL Receptor	Phase 2	Cystic Fibrosis

Autophagy

ID	CAS Number	Product Name	Target	Condition	Indication
T20879	109581-93-3	Tacrolimus monohydrate	Antibacterial; Antibiotic; Autophagy; Others; Phosphatase	Marketed; Phase 4	For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection; Moderate to Severe Atopic Dermatitis
T0087L	127-56-0	Sulfacetamide sodium	Antibacterial; Antibiotic; Autophagy	Marketed	Seborrhoeic Dermatitis
T15024	1309357-15-0	Silmitasertib sodium salt	Autophagy; Casein Kinase	Phase 2; Preclinical	Medulloblastoma, Childhood; Precursor B-cell lymphoblastic leukaemia-lymphoma
T0750	127-69-5	Sulfisoxazole	Antibacterial; Antibiotic; Autophagy; Endothelin Receptor	Marketed	Antibiotic(Urinary Tract Infections; Meningococcal Meningitis; Acute Otitis Media; Trachoma; Inclusion Conjunctivitis Nocardiosis; Chancroid; Toxoplasmosis; Malaria And Other Bacterial Infections.)

LRRK2

ID	CAS Number	Product Name	Target	Condition	Indication
T7729	1527473-30-8	PF-06454589	LRRK2		
T7196	1351758-81-0	HG-10-102-01	LRRK2		
T7155	1700693-08-8	JH-II-127	LRRK2		



Aurora Kinase

ID	CAS Number	Product Name	Target	Condition	Indication
T21981	880487-62-7	Phthalazinone pyrazole	Aurora Kinase		
T8685	T8685	SP-146	Aurora Kinase		
T6785	1207293-36-4	BI-847325	Apoptosis; Aurora Kinase; MEK	Phase 1 no development reported	Solid tumours
T6532	422513-13-1	Hesperadin	Aurora Kinase; Autophagy; Influenza Virus; Parasite		

TargetMol
YOUR TARGET MOLECULES
Cell Cycle / Checkpoint

ChK

ID	CAS Number	Product Name	Target	Condition	Indication
T21331	1184843-57-9	SAR-020106	Chk		
T7300	1196541-47-5	GDC-0575	Chk	Phase 1	Lymphoma; Solid tumours
T7080	1489389-18-5	CCT245737	Chk	Phase 2	Solid tumours
T6931	185039-89-8	PD0166285	Apoptosis; Chk; Wee1		
T6028	952021-60-2	PF 477736	Aurora Kinase; CDK; c-Fms; Chk; c-RET; FGFR; FLT; Src; VEGFR	Phase 1	Solid tumours
T4327	1234015-54-3	Prexasertib dihydrochloride	Apoptosis; Chk; S6 Kinase	Phase 2; Preclinical	Breast Cancer; Fallopian tube Cancer; Ovarian Cancer; Peritoneal Cancer; Small cell lung Cancer; Solid tumours; COVID 2019 infections
T4310	1234015-52-1	Prexasertib	Apoptosis; Chk	Phase 2; Preclinical	Breast Cancer; Fallopian tube Cancer; Ovarian Cancer; Peritoneal Cancer; Small cell lung Cancer; Solid tumours; COVID 2019 infections

CDK

ID	CAS Number	Product Name	Target	Condition	Indication
T17069	2139287-33-3	THAL-SNS-032	CDK		
T16363	1263373-43-8	NVP-2	Apoptosis; CDK		
T15732	1374639-75-4	Ribociclib succinate	CDK	Marketed; Phase 3	Advanced Breast Cancer; help slow the progression of Cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
T14919	1421693-22-2	CDKI-73	Apoptosis; CDK		
T14916	2079895-42-2	CDK2-IN-4	CDK		
T10436	2057509-72-3	AZD4573	CDK	Phase 1/2	Relapsed or Refractory Haematological Malignancies Including; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; High Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Richter's Syndrome; B-cell Non-Hodgkin Lymphoma; T-cell Non-Hodgkin Lymphoma; Small Lymphocytic Lymphoma; Multiple Myeloma

DNA - Methylation



Histone Methylation



Histone Acetylation



H4kzome Methylases:	H3K9me Methylases:	H3K27me Methylase:	H3K4me Methylase:	H3K36me Methylase:	H3K79me Methylase:
SET8/KAMT5A	PRDM3/KMT8E	Ezh2/KMT6	MLL1/KMT2A	NSD1/KMT3B	DOTIL/KMT4
MSD1/KMT3B	PPRDM16/KMT8F	NSD2/KMT3G	MLL2/KMT2B	SMYDZ/KMT3C	
Demethylases:	Demethylases:	Demethylase:	Demethylase:	Demethylase:	
JHDM1D/KDM7A	AOF1/KDM1B	JHDM1D/KDM7A	LSD1/KDM1A	JMJD1A/KDM2A	
PHF8/KDM7B	JMJD1A/KDM3A	PHF8/KDM7B	AOF1/KDM1B	JMJD1B/KDM2B	

Interactions Between Protein Modifications



Epigenetic Reader Domain

ID	CAS Number	Product Name	Target	Condition	Indication
T13363	2226534-49-0	Y06137	Epigenetic Reader Domain; PKC		
T12513	1629277-36-6	PNZ5	Epigenetic Reader Domain		
T12338	2231747-03-6	OXFBD04	Epigenetic Reader Domain		
T60155	2819989-68-7	PBRM1-BD2-IN-7	Epigenetic Reader Domain		
T60156	2819989-57-4	PBRM1-BD2-IN-2	Epigenetic Reader Domain		
T60157	2819989-75-6	PBRM1-BD2-IN-8	Epigenetic Reader Domain		
T4697	2138861-99-9	ABBV-744	Epigenetic Reader Domain; HIV Protease	Phase 1; Preclinical	Acute myeloid leukaemia; Prostate Cancer; Prostate cancer
T8658	2081072-29-7	NEO2734	Epigenetic Reader Domain; Histone Acetyltransferase	Preclinical	Cancer

Histone Demethylase

ID	CAS Number	Product Name	Target	Condition	Indication
T13748	63512-50-5	L-2-Hydroxyglutaric acid disodium	Histone Demethylase; Mitochondrial Metabolism		
T13055	1422535-52-1	T-3775440 hydrochloride	Histone Demethylase		
T7942	13492-01-8	Tranylcypromine hemisulfate	Histone Demethylase; MAO; Monoamine Oxidase	Marketed	major depressive episode without melancholia.
T6922	1431326-61-2	ORY1001	Histone Demethylase	Phase 2	Acute myeloid leukaemia; Small cell lung Cancer
T10983L	1831167-98-6	DDP-38003 dihydrochloride	Histone Demethylase		
T6593	1222800-79-4	ML324	Histone Demethylase; HSV; Others		
T6073	1357302-64-7	OG-L002	Histone Demethylase; HSV; Monoamine Oxidase		
T5825	1431303-72-8	Iadademstat dihydrochloride	Histone Demethylase	Phase 2; Preclinical	Acute myeloid leukaemia; Small cell lung Cancer; Solid tumours
T6847	1373422-53-7	GSK-J1	Histone Demethylase		

TargetMol
YOUR TARGET MOLECULES
Chromatin / Epigenetic

Histone Acetyltransferase

ID	CAS Number	Product Name	Target	Condition	Indication
T14073	1889279-16-6	A-485	Epigenetic Reader Domain; Histone Acetyltransferase		
T12345	2299226-01-8	CBP/p300-IN-3	Histone Acetyltransferase		
T12098	2055397-88-9	MOZ-IN-2	Histone Acetyltransferase		
T8344	357649-93-5	CPTH2	Apoptosis; Histone Acetyltransferase		
T5468	1311423-89-8	YF-2	Epigenetic Reader Domain; Histone Acetyltransferase; Others		
T4679	2055397-28-7	WM-1119	Histone Acetyltransferase		
T4362	2055397-18-5	WM-8014	Histone Acetyltransferase		
T3499	949912-58-7	Remodelin	Histone Acetyltransferase		

Histone Methyltransferase

ID	CAS Number	Product Name	Target	Condition	Indication
T16435	2514-30-9	PBIT	Histone Demethylase; Histone Methyltransferase		
T12428L	1616287-82-1	PF-06726304	Histone Methyltransferase		
T11486	2245255-66-5	GSK2807 Trifluoroacetate	Histone Methyltransferase		
T3257	1255580-76-7	UNC0638	Autophagy; Histone Methyltransferase; Influenza Virus		
T3099	1380288-87-8	Pinometostat	Histone Methyltransferase	Phase 1/2	Acute biphenotypic leukaemia
T3084	1687736-54-4	SGC707	Histone Methyltransferase		
T9742	2755823-12-0	SETDB1-TTD-IN-1	Histone Methyltransferase		
T17002	1467052-75-0	Tazemetostat hydrobromide	Histone Methyltransferase	Marketed	Follicular lymphoma; Sarcoma
T9700	2238821-31-1	EZH2-IN-2	Histone Methyltransferase		
T10882	902279-44-1	CPUY074020	Histone Methyltransferase		



Integrin

ID	CAS Number	Product Name	Target	Condition	Indication
T21781	280749-17-9	A-286982	Integrin		
T12783	162112-37-0	RWJ 50271	Integrin		
T10397	904763-27-5	ATN-161 trifluoroacetate salt	Integrin	Phase 2	Brain and Central Nervous System Tumors
TP1474	1313004-77-1	LXW7	Integrin		
TP1330	756500-23-9	Cyclo(RADfK)	Integrin		
TP1204	1392278-76-0	iRGD peptide	Integrin		
T8523	6975-75-3	ILK-IN-3	Integrin		
T7570	114681-65-1	RGD peptide (GRGDNP)	Apoptosis; Integrin		

Bcr-Abl

ID	CAS Number	Product Name	Target	Condition	Indication
T8488	2490599-18-1	GMB-475	Bcr-Abl		
T7861	895519-91-2	Flumatinib mesylate	Bcr-Abl; c-Kit; PDGFR	Marketed; Phase 4	Chronic myeloid leukaemia; chronic phase chronic myelogenous leukemia
T7186	916603-07-1	CZC-8004	Bcr-Abl		
T6348	940310-85-0	NVP-BHG712	Bcr-Abl; Ephrin Receptor; Raf; Src		
T6311	859212-16-1	Bafetinib	Autophagy; Bcr-Abl; Src	Phase 2	Bone resorption; Brain Cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate Cancer
T6300	856243-80-6	Degrasyn	Apoptosis; Autophagy; Bcr-Abl; DUB; JAK	Preclinical no development reported	Cancer; Glioblastoma; Pancreatic Cancer
T4618	890129-26-7	BGG463	Bcr-Abl; CDK		
T4320	895519-90-1	Flumatinib	Bcr-Abl; c-Kit; PDGFR	Marketed; Phase 4	Chronic myeloid leukaemia
T6230	152459-95-5	Imatinib	Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV	Marketed; Phase 2	Acute myeloid leukaemia; Fibroma; Malignant melanoma; Non-Hodgkin's lymphoma; Prostate Cancer; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
T5177	1492952-76-7	Asciminib	Bcr-Abl	Marketed; Phase 3	Chronic myeloid leukaemia; Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)

Microtubule Associate

ID	CAS Number	Product Name	Target	Condition	Indication
T3330L	94608-23-8	cis-trismethoxy Resveratrol	Microtubule Associated		
T17228	1332881-26-1	Sabizabulin	Microtubule Associated	Phase 3	Metastatic Castration-resistant Prostate Cancer
T28886	1477482-50-0	Suprafenacine	Microtubule Associated		
T10772	849550-05-6	Cevipabulin	Microtubule Associated	Phase 1	Tumors; Neoplasms
T9812	2415761-65-6	Tubulin inhibitor 24	Microtubule Associated		
T23889	578723-96-3	CID-663143	Microtubule Associated		



CDK

ID	CAS Number	Product Name	Target	Condition	Indication
T13584	1301708-12-2	BMVC-8C3O	DNA/RNA Synthesis		
T20945	94-75-7	2,4-D	DNA/RNA Synthesis		
T6501	75607-67-9	Fludarabine Phosphate	Apoptosis; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog	Marketed; Phase 4	Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
T8785	82186-71-8	HALOFUGINONE LACTATE	DNA/RNA Synthesis; TGF-beta/Smad	Phase 2	Duchenne muscular dystrophy
T7747	157000-76-5	Datelliptium chloride hydrochloride	DNA/RNA Synthesis		
T7655	69123-98-4	Fialuridine	DNA/RNA Synthesis		

DNA-PK

ID	CAS Number	Product Name	Target	Condition	Indication
T15789	1879887-96-3	LTURM34	DNA-PK; PI3K; PI4K		
T7122	2230820-11-6	AZD-7648	DNA-PK	Phase 1/2	Solid tumours
T7014	934493-76-2	Voxtalisib	DNA-PK; mTOR; PI3K	Phase 2	Chronic lymphocytic leukaemia; Glioblastoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
T6883	1386874-06-1	Samotolisib	Autophagy; DNA-PK; mTOR; PI3K	Phase 2	Endometrial Cancer; Non-small cell lung Cancer; Pancreatic Cancer; Prostate Cancer

DNA/RNA Synthesis

ID	CAS Number	Product Name	Target	Condition	Indication
T22667	749872-43-3	CID 5951923	DNA/RNA Synthesis		
T10936	688342-78-1	D-I03	DNA/RNA Synthesis		
T12935	1449597-34-5	SMN-C3	DNA/RNA Synthesis		
T10343	2089314-57-6	AOH1160	Apoptosis; DNA/RNA Synthesis		

HDAC

ID	CAS Number	Product Name	Target	Condition	Indication
T10244	1708113-43-2	ACY-1083	HDAC		
T10245	1609389-52-7	ACY-957	HDAC		
T16936	2245942-72-5	SS-208	HDAC		
T25175	1423058-85-8	BRD 9757	HDAC		

PPAR

ID	CAS Number	Product Name	Target	Condition	Indication
T15581	223132-37-4	Inolitazone	PPAR	Phase 2	Liposarcoma
T11339	85666-17-7	Furegrelate sodium	PPAR		
T11339L	85666-24-6	Furegrelate	PPAR		
T21764	161600-01-7	MCC-555	PPAR		
T22708	141200-24-0	Darglitazone	PPAR		
T23389	1338259-05-4	SR1664	PPAR		



Estrogen Receptor/ERR

ID	CAS Number	Product Name	Target	Condition	Indication
T10239	182167-02-8	Acolbifene	Estrogen Receptor/ERR	phase 3	Vasomotor Symptoms; Hot Flushes
T12654	151533-34-5	(Rac)-Acolbifene	Estrogen Receptor/ERR		
T11098	82413-20-5	Droloxifene	Estrogen Receptor/ERR		
T11237	2222844-89-3	Camizestrant	Estrogen Receptor/ERR	Phase 2	HER2-negative Breast Cancer
T39710	2229711-68-4	ARV-471	Estrogen Receptor/ERR	Phase 1/2	Breast Cancer
T12482	245124-69-0	Pipendoxifene hydrochloride	Estrogen Receptor/ERR	phase 2	Breast Cancer

TargetMol
YOUR TARGET MOLECULES
Endocrinology / Hormones

Glucocorticoid Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T15451	827319-43-7	GW-870086	Glucocorticoid Receptor	Phase 3	Asthma; Atopic Dermatitis
T8777	4419-39-0	Beclometasone	Glucocorticoid Receptor	Marketed; Phase 4	asthma
T8396	125-10-0	Prednisone acetate	Glucocorticoid Receptor	Marketed; Phase 4	anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, Nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant; Henoch-Sch?nlein Purpura Nephritis
T6580	1247-42-3	Meprednisone	Autophagy; Glucocorticoid Receptor	Marketed; Phase 2	Systemic lupus erythematosus, rheumatoid arthritis, nephrotic syndrome, ulcerative colitis, autoimmune hepatitis
T3962	79756-69-7	TPI-1	Glucocorticoid Receptor; Phosphatase		
T3316	426-13-1	Fluorometholone	Glucocorticoid Receptor	Marketed; Phase 4	Skin?diseases; Allergic and inflammatory eye disease
T3096	2181-04-6	Canrenoate potassium	Glucocorticoid Receptor	Marketed	Heart Failure
T1559	5593-20-4	Betamethasone dipropionate	Glucocorticoid Receptor	Marketed; Phase 4	Psoriasis
T15451	827319-43-7	GW-870086	Glucocorticoid Receptor	Phase 3	Asthma; Atopic Dermatitis

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T11560	1314796-00-3	hGPR91 antagonist 1	GHSR		
T13414	115730-24-0	ZT 52656A hydrochloride	Opioid Receptor		
T11857	2245072-21-1	LIT-001	Oxytocin Receptor		
T13865	41307-63-5	Resorcinolnaphthalein	RAAS		
T22355	55-03-8	L-Thyroxine sodium	Thyroid hormone receptor(THR)	Marketed; Phase 2	hypothyroidism.; Non-Alcoholic Fatty Live DiseaseDiabetes Mellitus, Type 2
T10084	1379445-54-1	CRTh2 antagonist 1	GPR		
T12320	1174985-59-1	ORL1 antagonist 1	Opioid Receptor		
T17114	82964-04-3	Tolrestat	Reductase	Withdrawn	control of certain diabetic complications
T26594	947331-05-7	Allisartan Isoproxil	RAAS	Marketed	Hypertension



Hedgehog Smoothened

ID	CAS Number	Product Name	Target	Condition	Indication
T14188	1357350-60-7	ALLO-2	Hedgehog/ Smoothened; Smo		
T2450	304909-07-7	SANT-1	Hedgehog/ Smoothened; Smo		
T2299	1059734-66-5	BMS-833923	Apoptosis; Hedgehog/ Smoothened; Smo	Phase 2	Chronic myeloid leukaemia
T2825	4449-51-8	Cyclopamine	Endogenous Metabolite; Hedgehog/ Smoothened; Smo	Preclinical Discontinued	Breast Cancer; Cancer

Adrenergic Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T0970	17659-49-3	Racanisodamine	AChR; Adrenergic Receptor	Marketed	Acute, Circulatory Shock
T13016	174689-39-5	SR59230A	Adrenergic Receptor		
T12643	109351-34-0	(R)-Terazosin	Adrenergic Receptor	Marketed	symptomatic benign prostatic hyperplasia and hypertension
T11318	86484-91-5	Dopexamine hydrochloride	Adrenergic Receptor	Phase 4	Oral Cancer; Head and Neck Cancer; Free Flap; Hypotension
T10952	219311-44-1	Dabuzalgron	Adrenergic Receptor; Apoptosis		
T0948	62-13-5	Adrenalone hydrochloride	Adrenergic Receptor	Marketed	Hemorrhage
T0852	51460-26-5	Carbazochrome sodium sulfonate	Adrenergic Receptor	Marketed	Capillary And Parenchymal?Hemorrhage

Adenosine Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T28861	496955-42-1	ST-1535	Adenosine Receptor		
T10058	531506-36-2	A2B receptor antagonist 1	Adenosine Receptor		
T23201	152529-79-8	PSB 1115	Adenosine Receptor		
T17117	340021-17-2	Tonapofylline	Adenosine Receptor	Phase 2	Renal Insufficiency, Heart Failure

EGFR

ID	CAS Number	Product Name	Target	Condition	Indication
T21946	134296-40-5	BIMU 8	5-HT Receptor		
T11075	170912-52-4	Donitriptan	5-HT Receptor		
T10169	261766-73-8	5-HT4 antagonist 1	5-HT Receptor		
T10162	120635-47-4	5-HT3 antagonist 3	5-HT Receptor		
T10170	334974-31-1	5-HT7 agonist 1	5-HT Receptor		
T12855	195199-95-2	SB 258719	5-HT Receptor		
T10824	7699-35-6	cis-Urocanic acid	5-HT Receptor	Phase 1	Non-muscle Invasive Bladder Cancer
T11183	263744-72-5	EMDT	5-HT Receptor		

Cannabinoid Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T10696	666261-80-9	CB2 modulator 1	Cannabinoid Receptor		
T28468	877202-74-9	PSNCBAM-1	Cannabinoid Receptor		
T22114	494844-07-4	NESS 0327	Cannabinoid Receptor		
T21861	358970-97-5	Drinabant	Cannabinoid Receptor	Phase 2	Schizophrenia
T22009	1314230-75-5	CB2 receptor agonist 2	Cannabinoid Receptor		
T10694	852315-00-5	CB1 inverse agonist 1	Cannabinoid Receptor		

Dopamine Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T27677	935776-74-2	JNJ-37822681	Dopamine Receptor	Phase 2	Schizophrenia
T10683	115092-85-8	Carmoxirole hydrochloride	Dopamine Receptor		
T60107	100935-99-7	N-0500 HCl	Dopamine Receptor		
T39429	202646-03-5	AHN 1-055 hydrochloride	Dopamine Receptor		
T21782	145307-34-2	A 77636 hydrochloride	Dopamine Receptor		
T11079	129024-87-9	NMI 8739	Dopamine Receptor		

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T8497	1648843-04-2	SX-682	CXCR	Phase 2	Metastatic Castration-resistant Prostate Cancer
T7681	878385-84-3	AZD-5069	CXCR	Phase 2	Bladder Cancer; Coronary disorders; Head and neck Cancer; Non-small cell lung Cancer; Solid tumours
T8702	99295-33-7	SKF-83566	5-HT Receptor; AChR; Dopamine Receptor		
T8633	1689-64-1	9-FLUORENOL	Dopamine Receptor		
T8901	423145-35-1	YUM70	Apoptosis; GPR; HSP		
T8748	914454-01-6	Exendin-4 acetate	Glucagon Receptor	Phase 4	Polycystic Ovary Syndrome



NOS

ID	CAS Number	Product Name	Target	Condition	Indication
T19916	25371-96-4	TRIM	NOS		
T7474	2942-42-9	7-Nitroindazole	NOS		
T3408	118-34-3	Syringin	Autophagy; NOS	Preclinical no development reported	Fatigue; Major depressive disorder
T2876	525-82-6	Flavone	Endogenous Metabolite; NOS		
T21700	165383-72-2	NOS-IN-1	NOS		
T21967	3979-00-8	MEG hemisulfate	NOS		

COX

ID	CAS Number	Product Name	Target	Condition	Indication
T23333	162054-19-5	SC-58125	COX		
T15645	101001-34-7	Pamicogrel	COX		
T11005	170569-87-6	Desmethyl Celecoxib	COX		
T0778	62-44-2	Phenacetin	COX	Marketed	Fever; Pain
T0758	36322-90-4	Piroxicam	COX	Marketed; Phase 4	Non-Steroidal Anti-Inflammatory Drug; Primary Dysmenorrhea
T0498	552-94-3	Salsalate	COX; Reactive Oxygen Species	Marketed; Phase 4	Inflammatory Disorders Such As Rheumatoid Arthritis, Or Noninflammatory Disorders Such As Osteoarthritis; Non Alcoholic Fatty Liver; Osteo Arthritis
T0484	169590-41-4	Deracoxib	Apoptosis; COX	Marketed; Preclinical no development reported	Inflammation; Pain
T0477	111406-87-2	Zileuton	COX; Ferroptosis; Lipoxygenase	Marketed; Phase 4	Asthma
T10032	134729-13-8	COX-2-IN-2	COX		
T10033	787623-48-7	COX-2-IN-1	COX		
T10355	68483-33-0	Apyramide	COX		

CCR

ID	CAS Number	Product Name	Target	Condition	Indication
T10639	1784252-84-1	C-021 dihydrochloride	CCR		
T21870	864289-85-0	C-021	CCR		
T10156	879399-82-3	CCR3 antagonist 1	CCR		
T26861	1202400-18-7	BMS-817399	CCR	Phase 2	Rheumatoid Arthritis

CXCR

ID	CAS Number	Product Name	Target	Condition	Indication
T26035	473722-68-8	rac-NBI-74330	CXCR		
T10905	1873376-49-8	CXCR2-IN-1	CXCR		
T12269	1060524-97-1	NUCC-390	CXCR		
T11179	688763-64-6	Elubrixin	CXCR; IL Receptor	Phase 2	Cystic Fibrosis

TargetMol
YOUR TARGET MOLECULES
Immunology / Inflammation

Histamine Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T16476	935840-31-6	PF-03654746	Histamine Receptor	Phase 2	Tourette's Syndrome
T27462	720691-69-0	GSK-239512	Histamine Receptor	Phase 2	Schizophrenia
T10000	79712-55-3	(±)-Tazifylline	Histamine Receptor		
T13352	113418-56-7	Wy 49051	Histamine Receptor		
TQ0046	929622-08-2	Bavisant	Histamine Receptor	Phase 2	Attention Deficit Hyperactivity Disorder
T26253	75970-99-9	Tecastemizole	Histamine Receptor		

Prostaglandin Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T15681	147776-06-5	L-161982	Prostaglandin Receptor		
T10031	851204-35-8	EP1-antagonist-1	Prostaglandin Receptor		
T21738	1221971-47-6	PF-9184	Prostaglandin Receptor		
T10960	139226-28-1	Darbufelone	LTR; Prostaglandin Receptor		

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T11699	353791-85-2	J-113863	CCR		
T22713	3733-63-9	Decloxizine	Histamine Receptor	Marketed	Allergic diseases, acute and chronic urticaria
T20712	546-06-5	Conessine	Histamine Receptor		
T14778	642008-81-9	BRD6989	CDK; IL Receptor; Interleukin		
T13410	667880-38-8	ZLDI-8	Apoptosis; Gamma-secretase; Immunology/Inflammation related; Phosphatase		
T12253	1610022-76-8	Nrf2-IN-1	Nrf2; Others		
T15433	1415925-18-6	GSK2795039	Apoptosis; NADPH; Reactive Oxygen Species; ROS		
T19916	25371-96-4	TRIM	NOS		



STAT

ID	CAS Number	Product Name	Target	Condition	Indication
T21267	28230-32-2	HODHBt	STAT		
T13009	2059952-75-7	STAT3-IN-1	Apoptosis; STAT		
T8719	882290-02-0	SC99	Apoptosis; JAK; STAT		
T8597	744270-00-6	ML116	STAT		
T8546	892686-59-8	BD750	JAK; STAT		
T60160	851095-32-4	STX-0119	STAT		
T21694	100324-81-0	(R)-Lisofylline	STAT	Phase 1/2	Type 1 Diabetes Mellitus
T27613	328998-77-2	inS3-54-A26	STAT		

JAK

ID	CAS Number	Product Name	Target	Condition	Indication
T17019	1260181-14-3	TCS 21311	GSK-3; JAK; PKC		
T14687	1609392-27-9	Deucravacitinib	IFNAR; Interleukin; JAK; Tyrosine Kinases	Phase 3	Psoriasis
T14331	1425381-60-7	Gusacitinib	JAK; Syk	Phase 2	Atopic Dermatitis
T12427	2140301-96-6	Brepocitinib P-Tosylate	JAK	Phase 2	Chronic Plaque Psoriasis
T8742	939681-36-4	G5-7	Apoptosis; JAK		
T8719	882290-02-0	SC99	Apoptosis; JAK; STAT		
T35341	1942919-79-0	NVP-BSK805 dihydrochloride	JAK		
T11710	2096999-92-5	JAK-IN-5	JAK		
T12549	916742-11-5	JAK-IN-11	JAK		
T13571	916741-98-5	JAK-IN-10	JAK		

EGFR

ID	CAS Number	Product Name	Target	Condition	Indication
T10534	2664214-60-0	BI-4020	EGFR		
T10802	2089381-40-6	CHMFL-EGFR-202	EGFR		
T10965	1226549-49-0	DBPR112	EGFR	Phase 1/2	Advanced Solid Tumor; Non Small Cell Lung Cancer
T11163	1226549-39-8	EGFR-IN-9	EGFR		
T12777	1423077-49-9	RTC-5	EGFR		
T35914	2252334-12-4	Epitinib succinate	EGFR	Phase 1	Solid Tumor

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T22431	186611-11-0	SU5204	EGFR; HER; VEGFR		
T11213	2071195-74-7	Epertinib hydrochloride	EGFR; HER		
T8742	939681-36-4	G5-7	Apoptosis; JAK		
T8719	882290-02-0	SC99	Apoptosis; JAK; STAT		



ERK

ID	CAS Number	Product Name	Target	Condition	Indication
T1933	362003-83-6	NVP 231	Apoptosis; ERK		
T21295	1265916-41-3	BIX02189	ERK; MEK		
T6948	839707-37-8	Pluripotin	ERK; Raf; S6 Kinase	Phase 1/2	Gastric Cancer
T6818	181223-80-3	DEL-22379	Apoptosis; ERK		
T2356	872573-93-8	Ro-3306	Apoptosis; CDK; ERK; PKA; PKC; SGK		
T21295	1265916-41-3	BIX02189	ERK; MEK		
T2027	548470-11-7	ISRIB	PERK		
T1956	865362-74-9	FR 180204	Apoptosis; ERK		

MEK

ID	CAS Number	Product Name	Target	Condition	Indication
T21295	1265916-41-3	BIX02189	ERK; MEK		
T7742	179246-08-3	GW 284543 hydrochloride	MEK		
T6971	946128-88-7	Ro 5126766	MEK; Raf	Phase 1	Multiple myeloma; Non-small cell lung Cancer; Solid tumours
T6843	1168091-68-6	GDC-0623	Apoptosis; MEK	Phase 1	Solid tumours
T6189	391210-10-9	Mirdametinib	Apoptosis; Autophagy; MEK	Phase 2; Preclinical	Chronic obstructive pulmonary disease; Neurofibromatoses
T2508	606143-89-9	Binimetinib	Autophagy; MEK	Marketed; Phase 3	Colorectal Cancer; Fallopian tube Cancer; Ovarian Cancer; Peritoneal Cancer; Malignant melanoma
T2443	212631-79-3	CI-1040	Apoptosis; MEK	Phase 2	Cancer
T2416	1094614-85-3	BIX02189	ERK; MEK; TGF-beta/Smad		
T21980	212631-61-3	PD 198306	MEK		

p38 MAPK

ID	CAS Number	Product Name	Target	Condition	Indication
T10990	10605-03-5	Dehydrocorydaline chloride	Autophagy; BCL; Caspase; p38 MAPK; Parasite; PARP		
T7667	449811-92-1	R1487	p38 MAPK		
T7661	1670-87-7	SD-169	p38 MAPK		
T7367	836683-15-9	Acumapimod	Autophagy; p38 MAPK		
T7276	271576-80-8	SD 0006	Autophagy; p38 MAPK		
T7030	139051-27-7	anemarsaponin B	COX; MEK; NF-κB; NO Synthase; p38 MAPK		
T2277	585543-15-3	Losmapimod	Autophagy; p38 MAPK	Phase 3	Acute coronary syndromes
T2118	354812-17-2	SC-514	Aurora Kinase; CDK; IκB/IKK; p38 MAPK; Serine Protease		
T1974	586379-66-0	PH-797804	Autophagy; p38 MAPK	Phase 2	Chronic obstructive pulmonary disease; Musculoskeletal pain; Neuropathic pain; Rheumatoid arthritis
T1764	152121-47-6	Adezmapimod	Autophagy; Mitophagy; p38 MAPK	Preclinical Discontinued	Cancer; Postmenopausal osteoporosis; Rheumatoid arthritis; Septic shock

JNK

ID	CAS Number	Product Name	Target	Condition	Indication
T14895	899805-25-5	Tanzisertib	JNK	Phase 2	Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Fibrosis; Interstitial Lung Disease; Lung Diseases, Interstitial
T13265	1139-83-9	Urolithin B	Akt; AMPK; Endogenous Metabolite; ERK; JNK; NF-κB		
T8477	312538-03-7	IQ-3	JNK		
T7677	894804-07-0	JNK Inhibitor VIII	JNK		
T2668	1410880-22-6	JNK-IN-8	c-Kit; JNK		
T2343	345987-15-7	AS601245	JNK	Phase 1 discontinued	Inflammation; Ischaemia
T2234	312917-14-9	TCS JNK 5a	Apoptosis; JNK		

Raf

ID	CAS Number	Product Name	Target	Condition	Indication
T11898	1800398-38-2	LXH254	Raf	Phase 2	Melanoma
T10157	835621-11-9	Regorafénib N-oxyde (M2)	c-Kit; c-RET; Drug Metabolite; PDGFR; Raf; VEGFR		
T0093L	284461-73-0	Sorafenib	Apoptosis; Autophagy; c-Kit; Ferroptosis; FLT; PDGFR; Raf; VEGFR	Marketed; Phase 1/2	Hepatocellular Carcinoma; Liver Cancer; Renal cell carcinoma; Thyroid Cancer
T0093	475207-59-1	Sorafenib tosylate	Apoptosis; Autophagy; c-Kit; Ferroptosis; FLT; PDGFR; Raf; VEGFR	Marketed; Phase 4	Hepatectomy; Hepatocellular Carcinoma; Sorafenib; Liver Cancer; Renal cell carcinoma; Thyroid Cancer
T1892	454453-49-7	Kobe2602	Raf; Ras		
T1886	1228591-30-7	TAK-632	Aurora Kinase; FGFR; PDGFR; Raf	Preclinical no development reported	Cancer; Malignant melanoma
T1876	436133-68-5	Kobe0065	Apoptosis; Raf; Ras		
T1851	208260-29-1	ZM 336372	Apoptosis; Raf		



Chloride channel

ID	CAS Number	Product Name	Target	Condition	Indication
T16346	1566-81-0	NS1652	Chloride channel		
T13059	552309-42-9	T16Ainh-A01	Chloride channel		
T10979	82749-70-0	DCPIB	Chloride channel; Potassium Channel		
T8039	60583-39-3	Brucine sulfate heptahydrate	Chloride channel		
T7638	107254-86-4	NPPB	Chloride channel		
T5225	300-84-5	Hypotaurine	Chloride channel; Endogenous Metabolite		

Potassium Channel

ID	CAS Number	Product Name	Target	Condition	Indication
T21487	150812-12-7	Retigabine dihydrochloride	Potassium Channel	Marketed; Phase 3	Epilepsy; Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
T17262	122955-13-9	XE 991 dihydrochloride	Others; Potassium Channel		
T16110	1928763-08-9	ML418	Potassium Channel		
T15758	105431-72-9	Linopirdine	Potassium Channel; TRP/TRPV Channel		
T15555	500715-03-7	IK1 inhibitor PA-6	Potassium Channel		
T15545	325457-89-4	ICA-27243	Potassium Channel		
T13320	1315380-70-1	VU591 hydrochloride	Potassium Channel		
T13316	1052515-91-9	VU0134992 hydrochloride	Potassium Channel		
T12478	85371-64-8	Pinacidil monohydrate	Potassium Channel	Marketed	hypertension
T10979	82749-70-0	DCPIB	Chloride channel; Potassium Channel		

Calcium Channel

ID	CAS Number	Product Name	Target	Condition	Indication
T6633	95635-55-5	Ranolazine	Calcium Channel; Sodium Channel	Marketed; Phase 3	Acute coronary syndromes; Atrial fibrillation; Type 2 diabetes mellitus; Angina pectoris
T12032	116666-63-8	Mibefradil dihydrochloride	Calcium Channel	Market Withdraw; Phase 1	Brain and Central Nervous System Tumors; For the treatment of angina and high blood pressure.
T16339	67812-42-4	Norverapamil hydrochloride	Calcium Channel; Drug Metabolite; P-gp		
T21454	55985-32-5	Nicardipine	Calcium Channel	Marketed; Phase 4; Preclinical	Cerebral Vasospasm; chronic stable angina; hypertension.; Pitt-Hopkins syndrome
T6577	89226-50-6	Manidipine	Calcium Channel	Marketed; Phase 4	Hypertension
T8867	1219927-22-6	RO2959 Hydrochloride	Calcium Channel; IL Receptor; Interleukin		

TargetMol
YOUR TARGET MOLECULES
Membrane Transporter / Ion Channel

Sodium Channel

ID	CAS Number	Product Name	Target	Condition	Indication
T19644	104-31-4	Benzonatate	Sodium Channel	Marketed	antitussive
T8711	1235406-03-7	PF-05186462	Sodium Channel		
T21996	241800-97-5	Zoniporide hydrochloride	Sodium Channel		
T8299	875313-64-7	Dimethyl lithospermate B	Sodium Channel		
T7811	88069-49-2	Pilsicainide HCl	Sodium Channel	Marketed; Not Applicable	cardiac arrythmia; Paroxysmal Atrial Fibrillation
T7547	202825-45-4	Ralfinamide mesylate	Sodium Channel	Phase 3	Pain
T7349	133865-88-0	Ralfinamide	Sodium Channel	Phase 3	Neuropathic pain
T7336	313254-51-2	ICA-121431	Sodium Channel		
T2342	934240-30-9	Raxatrigine	Sodium Channel	Phase 2	Trigeminal neuralgia
T2192	271-44-3	Indazole	Sodium Channel		
T9647	1788071-27-1	GX 201	Sodium Channel		
T16514	1079400-07-9	PF 04531083	Others; Sodium Channel	Phase 2	Post-surgical Dental Pain
T12655	1641574-26-6	(Rac)-AMG8379	Sodium Channel		
T8444	1356834-62-2	N-Me-aminopyridinone9	Sodium Channel		

TRP/TRPV Channel

ID	CAS Number	Product Name	Target	Condition	Indication
T22124	1002100-44-8	Oleoyl Serotonin	TRP/TRPV Channel		
T15628	917562-33-5	JT010	TRP/TRPV Channel		
T33429	878811-00-8	MK-2295	TRP/TRPV Channel	Phase 2	Pain, Postoperative; Tooth Extraction
T29522	808756-71-0	ABT 102	TRP/TRPV Channel		

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T6144	182004-65-5	KB-R7943 mesylate	Autophagy; Na+/Ca2+ Exchange		
T11014	672286-03-2	DFP00173	Aquaporin		
T13159	149845-07-8	Tiludronate disodium	ATPase	Marketed	osteitis deformans
T13365	912288-64-3	YHO-13351 free base	BCRP		



PDE

ID	CAS Number	Product Name	Target	Condition	Indication
T21865	686770-80-9	BC 11-38	PDE		
T15381	334826-98-1	Gisadenafil	PDE	Discontinued	Benign prostatic hyperplasia; Chronic obstructive pulmonary disease; Erectile dysfunction; Overactive bladder
T10415	2156655-68-2	Autotaxin-IN-3	PDE		
T12913	115344-47-3	Siguazodan	PDE		
T23638	100510-33-6	Adibendan	PDE		
T16379	778576-62-8	Oglemilast	PDE	Phase 2	Asthma
T10316	1187187-10-5	AN3199	Others; PDE		
T12395	2305087-92-5	PDE9-IN-1	PDE		

Dehydrogenase

ID	CAS Number	Product Name	Target	Condition	Indication
T23533	1477-57-2	WIN 18446	Dehydrogenase		
T22253	1448346-63-1	AG-120 (racemic)	Dehydrogenase	Marketed; Phase 3	acute myeloid leukemia (AML); Myelodysplastic syndromes
T19831	565-73-1	Sodium Oxamate	Apoptosis; CDK; Dehydrogenase		
T16384	1887014-12-1	Olutasidenib	Dehydrogenase; Isocitrate Dehydrogenase (IDH)	Phase 1/2	Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome
T16068	921605-87-0	MF-438	Dehydrogenase; Stearoyl-CoA Desaturase (SCD)		
T15435	1445879-21-9	GSK2837808A	Dehydrogenase		
T15022	1005334-57-5	CVT-10216	Dehydrogenase		
T14884	681159-27-3	CBR-5884	Dehydrogenase; Others		
T14878	944808-88-2	CAY10566	Dehydrogenase; Stearoyl-CoA Desaturase (SCD)		
T14501	2225819-06-5	BAY-2402234	Dehydrogenase; DNA/RNA Synthesis	Phase 1; Preclinical	Colorectal cancer; Lymphoma; Small cell lung cancer; Leukemia

P450

ID	CAS Number	Product Name	Target	Condition	Indication
T27617	897776-15-7	Inz-1	P450		
T41291	206052-02-0	MS-PPOH	P450		
T21548	1390637-82-7	PF-4981517	P450		
T10922	1356479-78-1	CYP11B2-IN-1	P450		
T10923	2093317-51-0	CYP17-IN-1	P450		
T10335	1186430-60-3	Antihistamine-1	P450		

Phospholipase

ID	CAS Number	Product Name	Target	Condition	Indication
T17218	172733-08-3	Varespladib methyl	Others; Phospholipase	Phase 2	Snake venom poisoning
T21777	1246303-14-9	VU0359595	Phospholipase		
T21681	149301-79-1	AACOCF3	Phospholipase		
T11149	381683-92-7	Ecopladib	Phospholipase		

PPAR

ID	CAS Number	Product Name	Target	Condition	Indication
T15581	223132-37-4	Inolitazone	PPAR	Phase 2	Liposarcoma
T11339	85666-17-7	Furegrelate sodium	PPAR		
T14176	475479-34-6	Aleglitazar	PPAR	Phase 3	Diabetes Mellitus Type 2, Kidney Disease, Chronic
T21764	161600-01-7	MCC-555	PPAR		
T22708	141200-24-0	Darglitazone	PPAR		
T23389	1338259-05-4	SR1664	PPAR		
T21587	331741-94-7	Muraglitazar	PPAR	Phase 3	Diabetes, Type 2
T12527	942594-93-6	Mavodelpar free base	PPAR		

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T21629	1977-10-2	Loxapine	5-HT Receptor; Dopamine Receptor	Marketed; Phase 4	Psychomotor Agitation; Schizophrenia; Bipolar Disorder; Schizophrenia
T20446	93-51-6	Creosol	Endogenous Metabolite		
T20257	121-98-2	Methyl anisate	Endogenous Metabolite		
T19418	62697-73-8	Methionine sulfoxide	Endogenous Metabolite	Marketed	Adjuvant therapy, such as cirrhosis and fatty liver, can also be used for acetaminophen poisoning and liver damage caused by drugs such as alcohol and sulfa.
T11557	2097262-60-5	FASN-IN-3	Fatty Acid Synthase		
T13092	863239-61-6	Tauro-Obeticholic acid	FXR		
T21344	73285-50-4	1-Deoxynojirimycin hydrochloride	Antibacterial; Antibiotic; Glucosidase; PI3K	Phase 2	Pompe Disease
T13130	52452-60-5	Terphenyllin	Glucosidase		
T16994	1260533-36-5	Pimitespib	HSP	Phase 1	Advanced Solid Tumors
T13554	289893-26-1	Arimoclomol maleate	HSP	Phase 3; Preclinical	Amyotrophic Lateral Sclerosis (ALS); Inclusion Body Myositis (IBM); Parkinson's disease
T11897	1033805-22-9	Telotristat ethyl	Hydroxylase	Marketed; Phase 3; Preclinical	Cholangiocarcinoma; Colorectal cancer; Liposarcoma; reduce serotonin levels, carcinoid syndrome.; Small Intestinal NET; Carcinoid Heart Disease
T11784	1402612-62-7	KT182	MAGL		



Antibacterial

ID	CAS Number	Product Name	Target	Condition	Indication
T67708	87-11-6	Thiolutin	Antibacterial; Antibiotic		
T11227	1207283-85-9	Eravacycline	Antibacterial	Marketed; Phase 2	Complicated Intra-abdominal Infections; Hematological Malignancy; Neutropenia
T16073	52093-21-7	Micronomicin	Antibacterial; Others	Marketed	Respiratory tract, urinary tract, abdominal cavity and trauma infection; Sepsis
T60171	1275582-98-3	Ibezapolstat hydrochloride	Antibacterial	Phase 2	Clostridium Difficile Infection
T12830	217477-25-3	Sapienic acid sodium	Antibacterial		
T10411	1338780-86-1	AU1235	Antibacterial		

Antibiotic

ID	CAS Number	Product Name	Target	Condition	Indication
T21771	25683-07-2	Pyoluteorin	Antibiotic		
T10329	2294013-78-6	anti-TB agent 1	Antibiotic		

Antifungal

ID	CAS Number	Product Name	Target	Condition	Indication
T16704	1340593-70-5	Quilseconazole	Others		
T10390	63631-36-7	Asperphenamate	Antifungal; Others		

HBV

ID	CAS Number	Product Name	Target	Condition	Indication
T5832	441785-25-7	Besifovir	HBV	Marketed; Phase 4	Hepatitis B; Hepatitis B; Besifovir Dipivoxil Maleate; Tenofovir Disoproxil Fumarate
T4475	1572510-42-9	JNJ-632	HBV		
T4121	118159-48-1	Bicyclol	Autophagy; HBV	Marketed; Phase 2; Preclinical no development reported	Fatty liver; Viral hepatitis; Liver Cancer

HCV

ID	CAS Number	Product Name	Target	Condition	Indication
T17029	1000787-75-6	Tegobuvir	HCV Protease	Phase 2	Hepatitis C, Chronic
T19862	1535212-07-7	Voxilaprevir	HCV Protease	Marketed; Phase 4	chronic Hepatitis C
T16088	443642-29-3	MK-0608	HCV Protease		
T15573	942123-43-5	Inarigivir soproxil	HCV Protease	Phase 2	HBV; Hepatitis B; Hepatitis B, Chronic

HIV

ID	CAS Number	Product Name	Target	Condition	Indication
T16764	431980-38-0	RN-18	HIV Protease		
T15436	1443460-91-0	GSK2838232	HIV Protease	Phase 2	Infection, Human Immunodeficiency Virus; HIV Infections
T10570	864953-39-9	Fostemsavir Tris	HIV Protease	Marketed	HIV Infections
T11451	186452-09-5	GPI-1046	HIV Protease; Others		



AChR

ID	CAS Number	Product Name	Target	Condition	Indication
T19084	830-81-9	1-Naphthyl acetate	AChE		
T14140	666-99-9	Agaric acid	AChR; Mitochondrial Metabolism		
T14094	135410-20-7	Acetamiprid	AChR		
T8868	360791-49-7	4BP-TQS	AChR		
T8770	525-57-5	Harmalol	AChR		
T8725	T8725	A 582941 HCl (848591-90-2(free base))	AChR		
T8585	5778-80-3	TA-03	AChE		
T6575	886047-22-9	LY2119620	AChR		

5-HT Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T21337	367514-87-2	Lurasidone	5-HT Receptor; Dopamine Receptor	Marketed; Phase 4	Bipolar Depression; schizophrenia.
T21231	154323-57-6	Almotriptan	5-HT Receptor	Marketed; Phase 4	acute migraine headache; Migraine Headaches
T21013	303-49-1	Clomipramine	5-HT Receptor	Marketed	obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette's disorder)
T16421	220643-77-6	p-MPPI hydrochloride	5-HT Receptor		
T8666	121679-13-8	Naratriptan	5-HT Receptor	Marketed; Phase 4	Naratriptan; Psychotic Disorders; Antisocial Personality Disorder; Impulse Regulation Disorder; Intermittent Explosive Disorder
T0031	138982-67-9	Ziprasidone hydrochloride monohydrate	5-HT Receptor; Adrenergic Receptor; Dopamine Receptor; Histamine Receptor; Norepinephrine	Marketed; Phase 4; Preclinical	Bipolar disorders; Schizophrenia; CNS disorders

Adrenergic Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T23283	109544-45-8	2-Methoxyidazoxan monohydrochloride	Adrenergic Receptor		
T8738	T8738	LUN42518 HCl 47142-51-8(free base)	Adrenergic Receptor		
T13016	174689-39-5	SR59230A	Adrenergic Receptor		
T12643	109351-34-0	(R)-Terazosin	Adrenergic Receptor	Marketed	symptomatic benign prostatic hyperplasia and hypertension
T11318	86484-91-5	Dopexamine hydrochloride	Adrenergic Receptor	Phase 4	Oral Cancer; Head and Neck Cancer; Free Flap; Hypotension
T10952	219311-44-1	Dabuzalgron	Adrenergic Receptor; Apoptosis		
T8810	23031-25-6	Terbutaline	Adrenergic Receptor	Marketed	reversible, obstructive airway disease
T21066	3414-63-9	Norepinephrine bitartrate salt	Adrenergic Receptor	Marketed	vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine. Also used as a vasopressor medication for patients with critical hypotension.

Dopamine Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T8702	99295-33-7	SKF-83566	5-HT Receptor; AChR; Dopamine Receptor		
T8633	1689-64-1	9-FLUORENOL	Dopamine Receptor		
T8423	1386162-69-1	ML417	Arrestin; Dopamine Receptor		
T8389	117-89-5	Trifluoperazine	Adrenergic Receptor; P-gp; Autophagy; CaMK; Dopamine Receptor; Influenza Virus	Marketed; Phase 1/2	anxiety disorders, depressive symptoms secondary to anxiety and agitation; Diamond Blackfan AnemiaPure Red Cell Aplasia
T8385	54143-57-6	Metoclopramide hydrochloride hydrate	5-HT Receptor; Dopamine Receptor	Marketed; Phase 2	gastroesophageal reflux disease (GERD); Hypoglycemia Unawareness
T4576	150915-41-6	Perospirone	5-HT Receptor; Dopamine Receptor	Marketed	Schizophrenia

Histamine Receptor

ID	CAS Number	Product Name	Target	Condition	Indication
T16476	935840-31-6	PF-03654746	Histamine Receptor	Phase 2	Tourette's Syndrome
T27462	720691-69-0	GSK-239512	Histamine Receptor	Phase 2	Schizophrenia
T10000	79712-55-3	(±)-Tazifylline	Histamine Receptor		
T13352	113418-56-7	Wy 49051	Histamine Receptor		
TQ0046	929622-08-2	Bavisant	Histamine Receptor	Phase 2	Attention Deficit Hyperactivity Disorder
T26253	75970-99-9	Tecastemizole	Histamine Receptor		

Others

ID	CAS Number	Product Name	Target	Condition	Indication
T19624	110958-19-5	Fasoracetam	GABA Receptor		
T12568	55476-47-6	PSB-12062	P2X Receptor		
T21422	73232-52-7	Methylnaltrexone bromide	Opioid Receptor	Marketed	constipation
T17222	342577-38-2	Velneperit	Neuropeptide Y Receptor	Phase 2	Obesity
T8907	25953-17-7	Minaprine dihydrochloride	MAO; Monoamine Oxidase	Marketed	antidepressant
T12717	802906-73-6	Basimglurant	GluR	Phase 1	Major Depressive Disorder



IκB/IKK

ID	CAS Number	Product Name	Target	Condition	Indication
T15559	1292310-49-6	TBK1/IKKε-IN-2	IκB/IKK		
T10477	2409479-29-2	BAY-985	IκB/IKK		
T8705	113760-29-5	BOT-64	IκB/IKK		
T8542	547757-23-3	BMS-345541 hydrochloride	IκB/IKK		
T7951	1893397-65-3	TBK1/IKKε-IN-5	IκB/IKK		
T1902	19542-67-7	BAY 11-7082	Apoptosis; Autophagy; DUB; IκB/IKK; Others		

NF-Kb

ID	CAS Number	Product Name	Target	Condition	Indication
T16974	1450833-55-2	TAK-243	Apoptosis; E1/E2/E3 Enzyme; NF-κB	Phase 1; Preclinical	Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Advanced Malignant Solid Tumors
T16706	2797-51-5	Quinoclamine	NF-κB		
T0907	599-79-1	Sulfasalazine	Antibacterial; Antibiotic; Apoptosis; Autophagy; COX; Ferroptosis; NF-κB	Marketed; Phase 4	Rheumatoid Arthritis
T0694	103177-37-3	Pranlukast	IL Receptor; Leukotriene Receptor; LTR; NF-κB; Others; TNF	Marketed	Allergic rhinitis; Asthma
T0646	89-57-6	5-Aminosalicylic Acid	COX; Endogenous Metabolite; Glutathione Peroxidase; Lipoxygenase; NF-κB; PAK; PPAR	Marketed; Phase 4	Ulcerative colitis
T0607	71939-50-9	Dihydroartemisinin	Apoptosis; Autophagy; NF-κB; Parasite	Marketed; Phase 4; Preclinical	malaria; Malaria; Anaemia; Systemic lupus erythematosus

NOD

ID	CAS Number	Product Name	Target	Condition	Indication
T0109	25717-80-0	Molsidomine	NOD	Marketed; Not Applicable	Angina Pectoris; Myocardial Ischemia
T7682	30315-93-6	Asymmetric dimethylarginine	Endogenous Metabolite; NO Synthase; NOD		

RIP Kinase

ID	CAS Number	Product Name	Target	Condition	Indication
T7504	852391-15-2	Necrostatin 2 racemate	RIP kinase	Preclinical	Human polyomavirus infections
T5401	1423186-80-4	GSK2983559 active metabolite	RIP kinase	Phase 1 Discontinued	Inflammatory bowel diseases
T9305	1391980-92-9	Necroptosis-IN-1	RIP kinase		
T11501	2361146-30-5	GSK840	RIP kinase		



PI3K

ID	CAS Number	Product Name	Target	Condition	Indication
T21992	351986-85-1	Vacuolin-1	Autophagy; PI3K		
T16567	1927857-61-1	PQR530	mTOR; PI3K		
T15789	1879887-96-3	LTURM34	DNA-PK; PI3K; PI4K		
T14998	1402152-13-9	Copanlisib dihydrochloride	Apoptosis; mTOR; PI3K	Marketed; Phase 3	Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; relapsed follicular lymphoma
T14511	1375469-38-7	BAY1082439	Apoptosis; PI3K	Phase 1	Neoplasms
T4079	934389-88-5	LY-294002 hydrochloride	PI3K	Preclinical Discontinued	Cancer

TargetMol
YOUR TARGET MOLECULES
PI3K / Akt / mTOR signaling

Akt

ID	CAS Number	Product Name	Target	Condition	Indication
T0033	58066-85-6	Miltefosine	Akt; HIV Protease; PKC	Marketed; Phase 4; Preclinical no development reported	Acanthamoeba infections; Chagas disease; Cancer metastases; Cutaneous leishmaniasis; Leishmaniasis; Visceral leishmaniasis; Cutaneous Leishmaniasis
T13265	1139-83-9	Urolithin B	Akt; AMPK; Endogenous Metabolite; ERK; JNK; NF-κB		
T6285	937174-76-0	GSK-690693	Akt; AMPK; Autophagy; PKC; Serine Protease	Phase 1	Lymphoma; Solid tumours
T6252	1001264-89-6	Ipatasertib	Akt	Phase 3	Breast Cancer; Prostate Cancer
T3132	871361-88-5	SC66	Akt; Apoptosis		
T2274	305834-79-1	SC79	Akt		
T2176	57-71-6	2,3-Butanedione 2-Monoxime	Akt		
T1961	1009298-59-2	Vistusertib	Akt; Apoptosis; Autophagy; mTOR; PI3K; S6 Kinase	Phase 2	Breast Cancer; Colorectal Cancer; Diffuse large B cell lymphoma; Fallopian tube Cancer; Gastric Cancer; Glioblastoma; Meningioma; Non-small cell lung Cancer; Ovarian Cancer; Peritoneal Cancer; Prostate Cancer; Renal Cancer; Small cell lung Cancer; Solid t

AMPK

ID	CAS Number	Product Name	Target	Condition	Indication
T16156	1179347-65-9	MT 63-78	AMPK; Apoptosis; mTOR		
T16099	1394371-71-1	MK8722	AMPK		
T8526	657-24-9	Metformin	AMPK; Autophagy; Mitophagy	Marketed; Phase 4; Preclinical	Choroideraemia; Diabetic retinopathy; Retinal disorders; Retinitis pigmentosa; Stargardt disease; Wet age-related macular degeneration; diabetes mellitus; Type 2 Diabetes Mellitus
T8476	140405-36-3	RSVA405	AMPK; Autophagy; STAT		
T0740	1115-70-4	Metformin hydrochloride	AMPK; Autophagy; Mitophagy	Marketed; Phase 4; Preclinical	Choroideraemia; Diabetic retinopathy; Retinal disorders; Retinitis pigmentosa; Stargardt disease; Wet age-related macular degeneration; Type 2 Diabetes Mellitus
T15137	2102672-22-8	DK419	AMPK; Wnt/beta-catenin		

mTOR

ID	CAS Number	Product Name	Target	Condition	Indication
T16567	1927857-61-1	PQR530	mTOR; PI3K		
T16156	1179347-65-9	MT 63-78	AMPK; Apoptosis; mTOR		
T11728	2411853-34-2	JR-AB2-011	mTOR		
T7343	1220699-06-8	PF-04979064	mTOR; PI3K		
T7166	1033735-94-2	GNE-493	mTOR; PI3K		
T1861	1086062-66-9	Omipalisib	Autophagy; mTOR; PI3K	Phase 1	Idiopathic pulmonary fibrosis; Lymphoma; Solid tumours
T1859	1009298-09-2	AZD-8055	Apoptosis; Autophagy; mTOR	Phase 1	Solid tumours
T1537	53123-88-9	Rapamycin	Antibiotic; Antifungal; Autophagy; Endogenous Metabolite; mTOR; Others	Marketed; Phase 4; Preclinical	Autoimmune disorders; Bladder cancer; Breast cancer; Cognition disorders; Lung cancer; Coronary artery restenosis; Lymphangioleiomyomatosis; Renal transplant rejection; Kasabach-Merritt syndrome; Systemic lupus erythematosus
T1784	159351-69-6	Everolimus	Apoptosis; Autophagy; mTOR; Others	Marketed; Phase 4	Angiomyolipoma; Astrocytoma; Breast Cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Partial epilepsies; Renal cell carcinoma; Renal transplant rejection; Autosomal dominant polycystic kidney disease; Liver Cancer; Myocardial infarction

GSK-3

ID	CAS Number	Product Name	Target	Condition	Indication
T14066	1034895-42-5	9-ING-41	Apoptosis; Autophagy; GSK-3	Phase 2; Preclinical	Colorectal cancer; Pancreatic cancer; Myelofibrosis
T11467	187325-53-7	GSK-3β inhibitor 1	GSK-3		
T8908	536-38-9	4-Chloro-2'-bromo acetophenone	GSK-3		
T8605	919936-70-2	GS87	GSK-3		
T7473	10075-50-0	5-Bromoindole	GSK-3		
T1755	603288-22-8	LY2090314	GSK-3	Phase 2	Acute myeloid leukaemia; Acute promyelocytic leukaemia; Pancreatic Cancer
T1741	612487-72-6	AZD1080	GSK-3	Phase 1 Discontinued	Alzheimer's disease
T10172	331467-03-9	5-Iodo-indirubin-3'-monoxime	CDK; GSK-3		



Hedgehog/Smoothened

ID	CAS Number	Product Name	Target	Condition	Indication
T14188	1357350-60-7	ALLO-2	Hedgehog/Smoothened; Smo		
T6891	935273-79-3	MK-4101	Apoptosis; Hedgehog/Smoothened; Smo	Phase 1 no development reported	Cancer
T6514	1095173-27-5	Glasdegib	Hedgehog/Smoothened; Smo	Marketed; Phase 3	Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis; Pani
T4211	2095432-58-7	SAG hydrochloride (912545-86-9(free base))	Hedgehog/Smoothened		

TGF-beta/Smad

ID	CAS Number	Product Name	Target	Condition	Indication
T8785	82186-71-8	HALOFUGINONE LACTATE	DNA/RNA Synthesis; TGF-beta/Smad	Phase 2	Duchenne muscular dystrophy
T8730	2001559-19-7	BMS986260	TGF-beta/Smad		
T8330	746667-48-1	BIO-013077-01	TGF-beta/Smad		
T7799	100874-08-6	BMP signaling agonist sb4	TGF-beta/Smad		
T7676	T7676	LSKL, Inhibitor of Thrombospondin TSP-1 acetate	TGF-beta/Smad		
T6337	446859-33-2	RepSox	ALK; TGF-beta/Smad		
T2048	396129-53-6	LY-364947	Casein Kinase; MLK; RIP kinase; TGF-beta/Smad		
T1763	356559-20-1	SB 525334	ALK; TGF-beta/Smad		

Wnt/beta-catenin

ID	CAS Number	Product Name	Target	Condition	Indication
T22775	1127442-87-8	exo-IWR-1	Wnt/beta-catenin		
T17142	84-82-2	Toxoflavin	Antibacterial; Antibiotic; Wnt/beta-catenin		
T8710	173436-66-3	MSAB	Wnt/beta-catenin		
T8400	40391-99-9	Pamidronic acid	Wnt/beta-catenin	Marketed; Phase 4	Ankylosing Spondylitis; Cancer metastases; Malignant hypercalcaemia; Osteitis deformans; Osteogenesis imperfecta; Osteoporosis; Postmenopausal osteoporosis

STAT

ID	CAS Number	Product Name	Target	Condition	Indication
T21267	28230-32-2	HODHBt	STAT		
T3218	83280-65-3	Napabucasin	STAT	Phase 3	Colorectal Cancer; Gastric Cancer; Non-small cell lung Cancer; Oesophageal Cancer; Pancreatic Cancer
T2896	546-43-0	Alantolactone	Apoptosis; STAT; TGF-beta/Smad		
T2867	512-04-9	Diosgenin	STAT		



c-Met/HGFR

ID	CAS Number	Product Name	Target	Condition	Indication
T10655	1357072-61-7	c-Met inhibitor 1	c-Met/HGFR		
T8825	1865733-40-9	Capmatinib 2HCl.H2O	c-Met/HGFR	Marketed; Phase 2	Glioblastoma; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours; Non-small cell lung Cancer
T8416	1029714-89-3	Capmatinib xHCl	c-Met/HGFR	marketed; Phase 2	Glioblastoma; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours; metastatic non-small cell lung Cancer (NSCLC) whose tumors have a mutation
T8399	1415560-69-8	Crizotinib hydrochloride	ALK; Autophagy; c-Met/HGFR; ROS; ROS Kinase	Marketed; Phase 4	locally advanced or metastatic non-small cell lung Cancer (NSCLC); Systemic Anaplastic Large-Cell Lymphoma

ALK

T16708	879487-87-3	R-268712	ALK; TGF-beta/Smad		
T8399	1415560-69-8	Crizotinib hydrochloride	ALK; Autophagy; c-Met/HGFR; ROS; ROS Kinase	Marketed; Phase 4	locally advanced or metastatic non-small cell lung Cancer (NSCLC); Systemic Anaplastic Large-Cell Lymphoma
T8387	1256589-74-8	Alectinib hydrochloride	ALK	Marketed; Phase 2	anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung Cancer (NSCLC) who have progressed on or are intolerant to crizotinib.; Solid tumours
T8152	6601-66-7	6-Demethoxy tangeretin	ALK; MAPK		
T8108	2141955-96-4	Blu-782	ALK	Phase 2	Fibrodysplasia ossificans progressiva
T6496	1352608-82-2	Vactosertib	ALK; TGF-beta/Smad	Phase 2	Fibroma; Gastric cancer; Non-small cell lung cancer
T6337	446859-33-2	RepSox	ALK; TGF-beta/Smad		
T6158	1062368-62-0	LDN-193189 HCl	ALK		

c-Kit

ID	CAS Number	Product Name	Target	Condition	Indication
T15199	1142363-52-7	Edicotinib	c-Fms; c-Kit; CSF-1R; FLT	Phase 2	Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
T8544	1048007-93-7	Masitinib mesylate	Apoptosis; c-Kit; FAK; FGFR; PDGFR; Src	Marketed; Phase 3	mast cell tumors in dogs.; Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Relapse Free
T8541	857890-39-2	Lenvatinib mesylate	c-Kit; c-RET; FGFR; PDGFR; VEGFR	Marketed; Phase 3; Preclinical	Benign prostatic hyperplasia; Hepatocellular Carcinoma; Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid Cancer. Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy. First-line treatment of unresectable hepatocellular carcinoma (HCC).
T8482	1442472-39-0	Ripretinib	Apoptosis; c-Kit; FLT; PDGFR; VEGFR	Marketed; Phase 3	Gastrointestinal Stromal Tumors; Glioblastoma; Solid tumours; Systemic mastocytosis
T7945	627908-92-3	SU14813	c-Kit; PDGFR; VEGFR		
T7861	895519-91-2	Flumatinib mesylate	Bcr-Abl; c-Kit; PDGFR	Marketed; Phase 4	Chronic myeloid leukaemia; chronic phase chronic myelogenous leukemia
T10651	2363169-01-9	c-Kit-IN-3	c-Kit		

c-RET

ID	CAS Number	Product Name	Target	Condition	Indication
T7418	882405-89-2	BBT594	c-RET		
T8541	857890-39-2	Lenvatinib mesylate	c-Kit; c-RET; FGFR; PDGFR; VEGFR	Marketed; Phase 3; Preclinical	Benign prostatic hyperplasia; Hepatocellular Carcinoma; Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid Cancer. Treatment o advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy. First-line treatment of unresectable hepatocellular carcinoma (HCC).
T8222	2152628-33-4	Selpercatinib	c-RET	Marketed; Phase 3	Medullary Thyroid CancerInfantile MyofibromatosisInfantile FibrosarcomaPapillary Thyroid CancerSof Tissue Sarcoma; Solid tumors
T8402	835621-07-3	Regorafenib Hydrochloride	Autophagy; c-RET; PDGFR; Raf; VEGFR	Marketed; Phase 4; Preclinical	Advanced Chemorefractory Colorectal Adenocarcinoma; metastatic colorectal Cancer (CRC); Rhabdomyosarcoma

FLT

ID	CAS Number	Product Name	Target	Condition	Indication
T16144	1429882-07-4	MRX-2843	FLT; Others	Phase 1; Preclinical	Advanced Cancer; Metastatic Cancer; Neoplasms; Neoplasm Metastasis; Neoplastic Processes; Pathologic Processes; Haematological malignancies
T15199	1142363-52-7	Edicotinib	c-Fms; c-Kit; CSF-1R; FLT	Phase 2	Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
T0374L	557795-19-4	Sunitinib	Apoptosis; Autophagy; c-Kit; FLT; IRE1; Mitophagy; PDGFR; VEGFR	Marketed; Phase 4	Clear-cell Metastatic Renal Cell Carcinoma; Gastrointestinal stromal tumours; Pancreatic Cancer; Renal cell carcinoma
T0093L	284461-73-0	Sorafenib	Apoptosis; Autophagy; c-Kit; Ferroptosis; FLT; PDGFR; Raf; VEGFR	Marketed; Phase 1/2	Hepatocellular Carcinoma; Liver Cancer; Renal cell carcinoma; Thyroid Cancer

Tie-2

ID	CAS Number	Product Name	Target	Condition	Indication
T6934	945614-12-0	Pexmetinib	Autophagy; p38 MAPK; Tie-2	Phase 1/2	Myelodysplastic syndromes
T2054	1345847-93-9	Altiratinib	c-Met/HGFR; FLT; Tie-2; Trk receptor; VEGFR	Phase 1; Preclinical no development reported	Glioblastoma; Solid tumours



E1/E2/E3 Enzyme

ID	CAS Number	Product Name	Target	Condition	Indication
T6332	905579-51-3	Pevonedistat	E1/E2/E3 Enzyme; NEDD8	Phase 3; Preclinical	Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Glioblastoma; Ovarian cancer; Renal cell carcinoma
T8816	864420-54-2	NAE-IN-M22	Apoptosis; E1/E2/E3 Enzyme		
T7379	144707-18-6	2-D08	E1/E2/E3 Enzyme; TAM Receptor		
T16974	1450833-55-2	TAK-243	Apoptosis; E1/E2/E3 Enzyme; NF-κB	Phase 1; Preclinical	Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Advanced Malignant Solid Tumors

Proteasome

ID	CAS Number	Product Name	Target	Condition	Indication
T17011	1446350-60-2	TCH-165	Proteasome		
T16684	58-60-6	Puromycin aminonucleoside	Aminopeptidase; Antibacterial; Antibiotic; Apoptosis; Proteasome		
T13858	1617495-03-0	RA190	Proteasome		
T12628	1211877-36-9	(R)-MG-132	Proteasome		
T12579	145888-79-5	RAMB4	Proteasome		
T1176	81110-73-8	Racecadotril	Neprilysin; Proteasome	Marketed; Phase 4	Diarrhoea
T8397	1239908-20-3	Ixazomib citrate	Autophagy; Proteasome	Marketed; Phase 3	Acute Leukemia Chronic Leukemia Myelodysplastic Syndrome Lymphomas Multiple Myeloma
T7854	205393-22-2	Bortezomib-pinanediol	Proteasome		
T6041	935888-69-0	Oprozomib	Autophagy; Proteasome	Phase 1/2	Haematological malignancies; Multiple myeloma
T6029	960374-59-8	ONX-0914	Antibacterial; HIV Protease; Proteasome	Preclinical no development reported	Autoimmune disorders; Haematological malignancies

DUB

ID	CAS Number	Product Name	Target	Condition	Indication
T7678	63388-44-3	SJB2-043	DUB		
T6925	882257-11-6	P005091	DUB	Preclinical	Cancer; Multiple myeloma; Muscular atrophy; Rheumatoid arthritis
T6697	30675-13-9	TCID	DUB		
T6107	314245-33-5	IU1	Autophagy; DUB		
T5461	2009273-67-8	GNE-6640	DUB		
T4634	2009273-71-4	GNE-6776	DUB		
T4338	1247825-37-1	USP7/USP47 inhibitor	DUB		
T4067	1431280-51-1	VLX1570	DUB	Phase 1/2; Preclinical no development reported	Multiple myeloma; Waldenstrom's macroglobulinaemia
T3951	157654-67-6	NSC632839	DUB		
T3555	1991986-30-1	ML364	DUB		

Global Sites



Fast delivery: 1-2 days for in-stock products